FGFR4 Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


FGFR4 Gene Editing    

FGFR4 (fibroblast growth factor receptor 4), also known as CD334, is a member of the fibroblast growth factor receptor family belonging to the highly conserved tyrosine kinase receptors. The full-length representative FGFR protein consists of an extracellular region consisting of three immunoglobulin-like domains, a hydrophobic transmembrane segment, and a cytoplasmic tyrosine kinase area. The extracellular portion of the protein interacts with FGFs, triggering a cascade of downstream signals that ultimately affect mitogenesis and differentiation.

Figure 1: The FGF/FGFR4 signal axis (Liwei Lang. 2019)

Typically, FGFR4 is highly expressed in embryonic tissues and is involved in embryonic development, angiogenesis, and tissue differentiation. In adult tissues, the expression of FGFR4 is restricted in actively growing tissues. The physiological role of FGFR4 in adults includes regulation of bile acid production, metabolism, muscle differentiation and tissue repair.

Studies have shown that FGFR4 is overexpressed and plays an importance role in many tumor such as prostate cancer, breast cancer, pancreatic cancer, pituitary cancer, hepatocellular carcinoma and gynecological tumors. And FGFR4 signaling is a prominent oncogenic pathway in various cancers and involved in carcinogenesis. The dysregulation of FGFR4 in cancer is summarized in the following sections, including altered expression, single nucleotide polymorphisms (SNPs), mutations, and abnormal regulation of FGFR4 ligands (Table 1). Therefore, targeting FGFR4 is a potential target for cancer treatment. FGFR4 targeting agents are making substantial progress with good anti-tumor activity, some of which are currently in pre-clinical development or early stages of clinical trials, but there is still a lack of markers predicting response to FGFR4-targeted therapies. More work is needed in the future to overcome the challenge of reducing the toxicity of FGFR4 targeting agents.

Table 1: Alterations of FGFR4 in diverse cancers (Shuya Tang. 2018)

Alteration Cancer type
OverexpressionBreast cancer, liver cancer, colon cancer, prostate cancer, rhabdomyosarcoma
Arg388Breast cancer, colorectal cancer, prostate cancer, OSCC, HNSCC
Y367CBreast cancer
K535Breast cancer
Aberrant regulation of FGFR4 ligand 
FGF19‐FGFR4Hepatocellular carcinoma, colorectal cancer

FGFR4 Gene Editing Service

CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. Based on our platform, we can help you effectively control target genes deleted, inserted or point mutated in cells or animals via CRISPR/Cas9 technology.

  • FGFR4 Gene Editing Cell Line Generation

We have successfully implemented FGFR4 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we will offer you full-length custom FGFR4 gene editing service from strategy design to final stable cells. Our FGFR4 gene editing cell line generation services include:

➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knockout/knockin/point mutation of FGFR4 by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report

Typically, we develop CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.

Other host cell lines available: Ba/F3, CHO, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.

  • FGFR4 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR-Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your projects’ needs, we provide a one-stop-shop FGFR4 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our FGFR4 gene editing animal model generation services include:

➢ FGFR4 gene conventional knockout animals
➢ FGFR4 gene conditional knockout animals
➢ FGFR4 point mutation animals
➢ FGFR4 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. There is no doubt that CRISPR/Cas9 PlatformCB will be your best partner to support your research.

Related Products at CRISPR/Cas9 PlatformCB

CLKO-0204FGFR4 KO Cell Lysate-HeLaInquiry
CSC-RT0699Human FGFR4 Knockout Cell Line-HeLaInquiry


  1. Shuya Tang. et al. Role of fibroblast growth factor receptor 4 in cancer. Cancer Sci. 2018; 109(10):3024-3031.
  2. Christine Heinzle. et al. Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy? Curr Pharm Des. 2014; 20(17):2881-2898.
  3. Alvaro Quintanal-Villalonga. et al. A patent review of FGFR4 selective inhibition in cancer (2007-2018). Expert Opinion on Therapeutic Patents. 2019; 29(6):429-438.
  4. Thisse B. et al. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol. 2005; 287(2):390-402.
  5. Liwei Lang & Yong Teng. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies. Cells. 2019; 8(1): 31.
For research use only. Not intended for any clinical use.


Verification code